Metformin in the prevention of preeclampsia
Phase 2
- Conditions
- preeclampsia.Pre-eclampsia
- Registration Number
- IRCT20230730058975N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 160
Inclusion Criteria
age 18 to 45
informed consent
having risk factors for preeclampsia
Exclusion Criteria
underlying disease like diabetes
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Preeclampsia. Timepoint: Every two weeks from the 12th week of pregnancy. Method of measurement: history taking and physical examination.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does metformin utilize to prevent preeclampsia in high-risk pregnancies?
How does metformin compare to standard-of-care treatments like low-dose aspirin in preventing preeclampsia?
Are there specific biomarkers that identify pregnant women who will benefit most from metformin to prevent preeclampsia?
What are the potential adverse events associated with metformin use during pregnancy for preeclampsia prevention?
What combination therapies or alternative drugs show promise alongside metformin for preeclampsia prevention in high-risk patients?